Skip to main navigation
elicio logo
  • Overview
  • News & Events
    Press Releases Events Presentations
  • Stock Information
    Stock Quote & Chart
  • Corporate Governance
    Documents & Charters Management Team Board of Directors Committee Composition
  • Financial & Filings
    SEC Filings
  • IR Resources
    Investor FAQs Email Alerts Contact IR

Investor Relations

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Corporate Profile

Elicio Therapeutics is a clinical-stage biotechnology company engineering investigational lymph node-targeted vaccines for an array of aggressive cancers and infectious diseases.

News Releases

November 9, 2023
Elicio Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Updates
November 3, 2023
Elicio Therapeutics Presents Updated Preliminary Immunogenicity Data from the Ongoing Phase 1 Study of ELI-002 and New Preclinical Data on ELI-007 and ELI-008 at the Society for Immunotherapy of Cancer (SITC 2023) Annual Meeting
October 11, 2023
Elicio Therapeutics Announces Upcoming Presentations at the Society for Immunotherapy of Cancer’s (SITC 2023) Annual Meeting
View All News

Events

October 2, 2023
T cell responses and clinical outcomes in pancreatic and colorectal cancer patients with Minimal Residual Disease in AMPLIFY-201, a Phase 1 trial of a first-in-class Amphiphile lymph node targeted mutant KRAS vaccine (AACR)
September 13, 2023 9:30 AM EDT
H.C. Wainwright 25th Annual Global Investment Conference
June 12, 2023
AMPLIFY-201, a first-in-human safety and efficacy trial of adjuvant ELI-002 2P immunotherapy for patients with high-relapse risk G12D- or G12R- mutated pancreatic and colorectal cancer (ASCO)
View All Events

Contact Investor Relations

Phone: +1 857-209-0153
Email: IR@elicio.com

  • © Elicio Therapeutics Inc. All Rights Reserved. 2023
  • Facebook
  • Twitter
  • LinkedIn
  • RSS